Search results for: Maria Lowe
Filter search results
Comparing the Cancer-Specific EORTC-8D and the Generic EQ-5D-3L
4 January 2017
…was higher (0.829) than for the EQ-5D-3L (0.748). This may be a function of the EORTC-8D having a higher ‘floor’, and the lowest possible health state value is 0.292 compared…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
…protocols, step therapy, and preferential formulary status as leverage to obtain lower prices and manage drug utilization. Much of the focus in this debate has been on drug prices….
OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates
3 December 2021
…directly set prices for branded medicines. Such policies would reduce global pharmaceutical revenues, leading to a reduction in pharmaceutical R&D expenditure and ultimately to lower levels of innovation. To support…
No Smoking Day 2022: Reflecting on OHE Projections from 1994
9 March 2022
…Comparing the predictions in OHE (1) and reality spawns several considerations. Firstly, the fact that the actual number of deaths is lower than the standard projection, despite the much larger…
Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
1 September 2020
…be covered at the lowest relevant cost-sharing level unless all drugs are priced higher than an established fair value threshold. (3) If all drugs in a class are priced so…
The Preventive Health Revolution: Insights from the 2024 Annual Lecture
15 October 2024
…was lowered by 20%, we would see a 1.14% increase in GDP after 5 years. The research also shows that these diseases skew towards lower income deciles – so tackling…
The Economics of Elevated Hospital Mortality at Weekends
10 June 2015, 11:00pm
…2011-31st March 2014, we show that attendance volumes and admission probabilities are significantly lower at weekends compared to weekdays. Taking account of these sources of variation in patient selection substantially…
Biosimilars’ Price Dynamic in Europe
30 June 2010
…For example, since growth hormone is given primary to children and effects are visible only over the longer term, tolerance of risk and reduced efficacy is lower. EPO and insulin, in…
Estimating US Savings from Biosimilars
13 July 2010
…to interchangeability, market share will grow more slowly even in the face of lower prices if the FDA judges a biosimilar not to be fully interchangeable. Omnitrope, a biosimilar human growth hormone…